BioMérieux
BioMérieux Obtains CE Mark for Semi-Quantitative SARS-CoV-2 Serology Test
The company said that an evaluation involving the Pfizer-BioNTech and Moderna vaccines showed that the test can detect SARS-CoV-2 IgG antibodies post-vaccination.
BioMérieux Receives CE Mark for Vitek Clinical Microbiology Mass Spec System
The company said it plans to launch the instrument in selected European and Asian markets in the second half of 2021, with a global launch planned for 2022.
BioMérieux Reports 10 Percent Q1 Revenue Growth, Lowers Full-Year Guidance
The firm now guides for neutral to mid-single digit growth in 2021, decreased from a prior range of 5 percent to 8 percent growth.
BioMérieux Gets CE Mark for Three Dengue Immunoassays
The three tests run on the firm's Vidas systems and expand the firm's footprint in vector-borne disease.
BioMérieux Interferon Gamma Release Assay for Latent TB Gets CE Mark
The test is fully automated from sample to result interpretation and requires one whole-blood sample tube with no manual sample preparation necessary.
Feb 24, 2021
BioMérieux Reports 21 Percent Revenue Growth in Q4
Oct 22, 2020